BrainStorm Cell Therapeutics Opens New Onsite Animal House

NEW YORK & PETACH TIKVAH, Israel--(Business Wire)--
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading
developer of adult stem cell technologies and therapeutics, is pleased
to announce the opening of a new animal house located at BrainStorm's
research headquarters in Petach Tikvah, Israel.

The animal house will serve as an onsite location for the
Company's animal testing for developing their patented technologies to
treat Parkinson's and ALS. The new construction will allow the Company
to conduct trials more quickly and efficiently.

The animal house was built and will be operated in accordance with
the guidelines of The National Institute of Health to ensure the
animal's welfare and the validity of the research data. A
representative from the Israeli council on animal experimentation
assessed the animal house, and determined that all Israeli regulations
were adhered to.

"The opening of the onsite animal house places BrainStorm in a
stronger position amongst others in the stem cell sector," commented
Rami Efrati, Company CEO.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company
developing adult stem cell therapeutic products, derived from
autologous (self) bone marrow cells, for the treatment of
neurodegenerative diseases. The NurOwn(TM) patent pending technology
is based on discoveries made by the scientific team led by prominent
neurologist Professor Eldad Melamed, Head of Neurology at Rabin
Medical Center, and expert cell biologist Dr. Daniel Offen, Head of
the Neuroscience Laboratory at the Felsenstein Medical Research Center
of Tel-Aviv University. The technology allows for the differentiation
of bone marrow-derived stem cells into functional neurons and
astrocytes, as demonstrated in animal models. The Company holds rights
to develop and commercialize the technology through an exclusive,
worldwide licensing agreement with Ramot at Tel Aviv University Ltd.,
the technology transfer company of Tel-Aviv University. The Company's
initial focus is on Parkinson ALS and Spinal Cord Injury, although its
technology has promise for treating several others diseases including
MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s
actual results to differ materially from those stated or implied by
such forward-looking statements, including BrainStorm's ability to
complete its equity financing transactions previously disclosed,. The
potential risks and uncertainties include, among others, risks
associated with BrainStorm Cell Therapeutics Inc.'s limited operating
history, history of losses and expectation to incur losses for the
foreseeable future; dependence on its license to Ramot's technology;
ability, together with its licensor, to adequately protect the
NurOwn(tm) technology; dependence on key executives and on its
scientific consultants; ability to identify, negotiate and
successfully implement strategic partnering relationships; ability to
complete clinical trials successfully and to obtain required
regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining
regulatory approval for treatments in BrainStorm Cell Therapeutics
Inc.'s market; the limited public trading market for BrainStorm Cell
Therapeutics Inc.'s stock which may never develop into an active
market; and other factors detailed in BrainStorm Cell Therapeutics
Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB,
current reports on Form 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to
the Company. The Company does not undertake any obligation to update
forward-looking statements made by us.

BrainStorm Cell Therapeutics Inc.
Chaim Levinson, +972-545-633683
Clevinson@brainstorm-cell.com

Copyright Business Wire 2008